Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.
Amgen and Generate announced a deal worth potentially $1.9bn focused on AI/ML in drug development • Source: Shutterstock